Ingevity 10-Q: Q3 EPS $1.41, EBITDA Outlook Narrowed to $385-$395M
NGVT sits 39% above its 52-week low of $45.85 on elevated volume (3.2× avg).
Summary
Ingevity's Q3 10-Q confirms $1.41 diluted EPS and $305.1 million of sales, narrows 2026 adjusted EBITDA to $385-$395 million, and shows nine-month operating cash flow cut to $83.4 million by the $113.2 million BASF settlement.
Key Events · Earnings and Guidance · NGVT
-
Q3 Earnings Confirmed in 10-Q
Net sales of $305.1 million, net income of $49.3 million and diluted EPS of $1.41; nine-month net income was $144.4 million versus a $82.5 million loss a year earlier.
-
EBITDA Outlook Narrowed
Full-year 2026 adjusted EBITDA guidance narrowed to $385-$395 million, holding the midpoint of the prior $380-$400 million range; net sales expected at roughly $1.1 billion.
-
Cash Flow Hit by BASF Payment
Nine-month operating cash flow fell to $83.4 million from $234.1 million, driven by a $113.2 million litigation settlement payment made April 1, 2026.
-
Buybacks Continue
Repurchased $126.3 million of stock in nine months (1,804,168 shares at $69.44 average), leaving $172.2 million unused under the 2022 authorization.
Analysis · NGVT · Industrial Applications And Services
The 10-Q puts full numbers behind the November 4 earnings release. Q3 net income was $49.3 million, or $1.41 diluted, on net sales of $305.1 million, and nine-month net income swung to $144.4 million from a $82.5 million loss a year earlier that carried a $183.8 million goodwill impairment. Cash is the bigger story: nine-month operating cash flow fell to $83.4 million from $234.1 million, mostly because of the $113.2 million BASF litigation settlement paid on April 1, 2026. Management narrowed 2026 adjusted EBITDA to $385-$395 million while keeping the midpoint of the prior $380-$400 million range, and it is still working off roughly $20 million of stranded costs from the divestitures, having eliminated about 65% on an annualized run-rate basis through Q3. Buybacks stayed aggressive at $126.3 million for nine months, with $172.2 million left on the authorization.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGVT was trading at $63.71 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $45.85 to $79.29. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.